Why Pfizer’s Abrysvo quietly changes RSV protection for older adults

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-20, 13:14. Details in the imprint.

With Abrysvo, Pfizer wants to give adults over 60 and certain high-risk patients a quieter RSV season, ideally without wheezing nights and hospital corridors. The recombinant protein vaccine packs a bivalent F protein design that aims squarely at the lungs where RSV really hurts.

What Abrysvo is built to do

Abrysvo is a bivalent RSV prefusion F protein vaccine that targets RSV A and RSV B strains with stabilized antigens, aiming to trigger strong neutralizing antibodies in older adults. Each dose contains 120 micrograms of antigen with an aluminum-based adjuvant for extra immune punch.

The vaccine is given as a single 0.5 ml intramuscular injection for adults 60 and older in the US, usually before RSV season to get ahead of winter waves. In Europe, regulators have also cleared it for use in adults over 60 and certain at-risk groups.

Efficacy that calms RSV worries

In the pivotal Phase 3 RENOIR trial, Abrysvo cut the risk of RSV-related lower respiratory tract disease with at least two symptoms by about 66.7 percent in adults 60 and older. Protection against severe disease with at least three symptoms reached roughly 85.7 percent in the first RSV season.

That means fewer deep, rattling coughs that end in the emergency room, especially for people with heart and lung conditions. The data show protection remains acceptable into a second season, though the effect tapers, and booster strategies are being evaluated.

Side effects and what patients actually feel

Most people report classic vaccine reactions at the injection site such as pain, redness, or swelling, alongside systemic effects like fatigue, headache, and mild muscle aches. In clinical studies these were usually short-lived, clearing within a few days without treatment.

Rare but serious events like Guillain-Barré syndrome have been observed in a small number of older participants, which regulators are tracking in post-marketing safety studies. For many high-risk patients, physicians weigh those rare signals against the concrete RSV hospitalization risk that rises sharply with age.

Where Abrysvo fits versus rivals

In the crowded RSV space, Abrysvo goes up against GSK’s Arexvy and emerging mRNA and monoclonal approaches. Unlike monoclonal antibodies for infants, Pfizer positions Abrysvo for older adults and, in a separate indication, for maternal immunization to protect newborns via placental antibody transfer.

Clinically, its efficacy numbers sit in the same ballpark as Arexvy, though the trials are not directly comparable. Physicians often look at nuances like safety profile, scheduling, and supply in local clinics when deciding which RSV shot to stock.

Pricing, access, and who gets it

In the US, Abrysvo’s list price sits in the low to mid-hundreds of dollars per dose, broadly aligned with other adult RSV vaccines, with many older adults covered through Medicare and private plans. Outside the US, pricing and reimbursement vary sharply by country and health system decisions.

Germany’s STIKO and other national bodies are still refining RSV recommendations, so availability may be limited or focused on specific risk groups depending on national guidance. For now, the most consistent access is in the US and other high-income markets where RSV seasons strain hospital capacity almost every winter.

Pfizer context and stock perspective

For Pfizer, Abrysvo is part of a broader push to diversify beyond COVID-19, alongside pneumococcal vaccines and oncology launches that aim to stabilize revenue over the next few years. Shares of Pfizer Inc. (US7170811035) trade on the NYSE in US dollars.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.